American Oriental Bioengineering Inc. (OTCMKTS:AOBI) Cut to Sell at ValuEngine

American Oriental Bioengineering Inc. (OTCMKTS:AOBI) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday, July 17th.

Shares of American Oriental Bioengineering (OTCMKTS AOBI) opened at 1.11 on Monday. American Oriental Bioengineering has a 52-week low of $1.02 and a 52-week high of $5.40. The stock has a 50 day moving average of $3.08 and a 200 day moving average of $3.94. The company’s market cap is $79920.00.

TRADEMARK VIOLATION NOTICE: “American Oriental Bioengineering Inc. (OTCMKTS:AOBI) Cut to Sell at ValuEngine” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at

About American Oriental Bioengineering

American Oriental Bioengineering, Inc is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about American Oriental Bioengineering Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for American Oriental Bioengineering Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit